# Junta clínica — PT-pseudo_0615b2bd8504 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_0615b2bd8504",
  "pid": "PT-pseudo_0615b2bd8504",
  "task": 1,
  "psa": 160.0,
  "age": 63,
  "months": 1,
  "pirads": "5",
  "psad": 2.635,
  "psav": 35.73,
  "psap": 115.9,
  "vol": 60.71,
  "dre": "Abnormal",
  "bx": "Positive",
  "cspca": 0.95889634,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "93 kg",
    "height": "191 cm",
    "bmi": "25.5",
    "bp": "140/81 mmHg",
    "hr": "48 bpm",
    "smoking": "Current smoker (20 pack-yr)",
    "last_dental": "2 yr ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "26 Jan 2025",
  "enc_ref": "Dr. C. Peters (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment."
    },
    {
      "s": "History",
      "t": "Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket \"Positive\" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly."
    }
  ],
  "occupation": "retired bank clerk",
  "marital": "Married",
  "living": "Lives in ground-floor apartment with partner",
  "next_of_kin": "Sibling (brother)",
  "recent_other": [
    "Audiology — hearing test",
    "Orthopaedic outpatient — knee follow-up",
    "Memory clinic — baseline screening"
  ],
  "alcohol": "14 units / week",
  "exercise": "Light weight-training at home, 2x/week",
  "ipss": "IPSS score: 10/35 (moderate LUTS)",
  "admin": "Patient self-employed; flexible appointment slots requested.",
  "mri_hospital": "Amsterdam UMC (location AMC)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_0615b2bd8504
Task: 1

Encounter: Urology - outpatient on 26 Jan 2025.
Referrer: Dr. C. Peters (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 160.0 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 2.635 ng/mL²
  - PSA velocity: 35.73 ng/mL/yr
  - Prior PSA: 115.9 ng/mL
  - Prostate volume: 60.71 mL
  - Months since last PSA: 1
  - DRE findings: Abnormal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.95889634 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 160 ng/mL. PI-RADS 5. PSAD 2.63. Prostate volume 61 mL. DRE abnormal. csPCa 0.96.

Vitals: weight 93 kg, height 191 cm, BMI 25.5, BP 140/81 mmHg, HR 48 bpm. Smoking: Current smoker (20 pack-yr).

Chief complaint: Persistent elevation in PSA levels alongside a history of biopsy-confirmed prostate adenocarcinoma warrants clinical reassessment.

History: Now aged 63-year-old, the individual works as a retired bank clerk and Lives in ground-floor apartment with partner. Following an initial PSA measurement of 55.0 ng/mL in late 2022, a prior biopsy bucket "Positive" was documented. He maintains a Married status and engages in light resistance training twice weekly, complemented by a moderate alcohol intake of 14 units per week. Current smoker (20 pack-yr) status is noted, though he explicitly denies haematuria, pelvic discomfort, or lower urinary tract symptoms exceeding a baseline IPSS of 10. Past medical reviews include a routine hearing evaluation, an orthopaedic check for stable knee osteoarthritis, and a memory clinic assessment revealing intact cognition. He has never utilized 5-alpha-reductase inhibitors. General health remains excellent with an ECOG performance status of 0. Comorbidities: none. Active medication: None.

Physical examination: DRE — texture: firm and irregular nodule palpable in the left posterior peripheral zone; mobility: fixed; asymmetry: pronounced enlargement with right lobe induration but no distinct discrete masses; overall classification: cT3a. Abnormal DRE confirmed. Vital signs record a blood pressure of 140/81 mmHg and a resting heart rate of 48 bpm. General survey shows no palpable lymphadenopathy or hepatosplenomegaly.

Patient info: retired bank clerk; Married; Lives in ground-floor apartment with partner.
Next of kin: Sibling (brother).

Lifestyle: alcohol 14 units / week; exercise Light weight-training at home, 2x/week; IPSS score: 10/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Orthopaedic outpatient — knee follow-up; Memory clinic — baseline screening.
Admin: Patient self-employed; flexible appointment slots requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: NO BIOPSY   p(biopsy) = 0.40
  uncertainty  +/- 0.18 epistemic (95% band 0.04-0.75); among patients I cannot tell apart the outcome was 0.97 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

What moved me most, across the labelled series: prior positive biopsy, PI-RADS >= 4, no prior biopsy, pmhx_hypercholesterolaemia, suspicious DRE, number of comorbidities. I read 39 variables, all
from the panel — nothing from the mpMRI prose, the PSA trajectory, the previous notes or the
laboratory. Out-of-fold over 91 labelled cases: AUC 0.758, balanced
accuracy 0.625.

The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. My criterion answers DEFER.

The criterion: PSA >= 20 ng/mL in a man with a tissue diagnosis: the next step is staging and treatment, not more tissue. In the labelled series this criterion matched the reading urologist in 5 of 6 cases in exactly this situation.

Like Expert 1, I have read ONLY the visible panel — not the mpMRI prose, the PSA trajectory, the
previous notes or the laboratory panel. Departing from me needs a specific finding from a document
somebody actually opened, named out loud; not a restatement of the panel numbers I already used.

## Intervención 5 — EXPERT-LIBRARY

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

The case library holds 49 labelled men in this same situation (Positive prior biopsy). The 3 closest by panel distance, and what the reading urologist did:
  1. distance 0.00 — IDENTICAL PANEL: this is the same case, already in the labelled series: PI-RADS 5, PSA 160.0, PSAD 2.635, age 63, DRE Abnormal -> DEFER (clear). He wrote: "Start treating the patent. It does not make sense to not treat this man initially."
  2. distance 0.72: PI-RADS 5, PSA 190.0, PSAD 4.097, age 66, DRE Nodus -> DEFER (clear). He wrote: "Patient with a clear PCa diagnosis. Do PSMA-PET and start hormontreatment"
  3. distance 0.79: PI-RADS 5, PSA 113.0, PSAD 2.61, age 67, DRE Nodus -> DEFER (clear). He wrote: "Patient has a verified PCa with PSA 113. Start treatment and do I PSMA-PET for further workup."

PRECEDENT: DEFER. The nearest precedent is this very patient, so the library returns what the reading urologist actually did with him. That is a record, not a judgement; out of sample this expert is worth only what the distance is worth.

What the precedents are FOR: they show what this urologist looks at and how he phrases the call. What they are NOT: facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. This patient is in the labelled series, so what follows is the reading urologist's own trace for him, not a prediction.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.
WHAT HE WEIGHS: vol=noted, pirads=decisive, age=important, dre=noted, psa=decisive, bx=decisive.
HOW SURE HE USUALLY IS: clear.

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that a PI-RADS score of 3 or higher is used to trigger a biopsy. The guideline states, "A PI-RADS threshold of $\\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
Expert 1's suggestion of no biopsy is based on a classifier that weighs variables present on the panel but ignores the context of the PI-RADS 5 finding and the prior positive biopsy. Expert-Cohort's criterion, which defers based on a prior positive biopsy, is a strong clinical rule that the guideline supports.

WHAT WE STILL NEED
The prior biopsy status is 'Positive', which is a fact that the guideline makes decisive. The guideline requires establishing the grade of the prior biopsy and the number and dates of biopsy sessions in the notes to determine the next step. The PSA value of 160.0 ng/mL is a fact that the guideline makes decisive. The PI-RADS score of 5 is a fact that the guideline makes decisive. The prostate volume of 60.71 mL is a fact that the guideline makes decisive. The DRE finding is 'Abnormal' is a fact that the guideline makes decisive.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

This case strongly hinges on establishing the grade and history of the prior positive biopsy to determine the appropriate next step according to the EAU guidelines.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> What is the lesion size and zone of the PI-RADS 5 lesion, and is there extraprostatic extension?
  psa_trend (get_psa_trend) -> What is the trend of the serial PSA values beyond the headline value of 160.0 ng/mL?
  previous_notes (get_previous_notes) -> What was the Gleason/ISUP grade of the prior biopsy, how many biopsy sessions occurred, and is there a surveillance protocol in place?
  laboratory_results (get_lab_results) -> What are the full results for free-PSA fraction, renal function, and haemoglobin?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade (Gleason or ISUP) of the prior positive biopsy?
  Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due?
  Q3. Given the PI-RADS 5 and prior positive biopsy, does the patient meet the criteria for immediate treatment as suggested by the closest precedent?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
Subject: Prostate Multiparametric MRI | Date: 20 January 2025 | Facility: Amsterdam UMC (AMC)
What is the lesion size and zone of the PI-RADS 5 lesion, and is there extraprostatic extension?
The lesion spans roughly 35 mm at its widest point in the left peripheral zone, and suspicion for extracapsular extension centers on the left posterolateral margin.

psa_trend
What is the trend of the serial PSA values beyond the headline value of 160.0 ng/mL?
The trend shows values of 14.8 ng/mL on Aug 2022, 18.9 ng/mL on Jun 2023, 12.0 ng/mL on Apr 2024, and 160.0 ng/mL on Jan 2025.

previous_notes
What was the Gleason/ISUP grade of the prior biopsy, how many biopsy sessions occurred, and is there a surveillance protocol in place?
The Gleason/ISUP grade of the prior biopsy was Gleason 3+4 pathology, and one biopsy session occurred. There is no surveillance protocol mentioned.

laboratory_results
What are the full results for free-PSA fraction, renal function, and haemoglobin?
Free PSA is 16.71 ng/mL, %Free PSA is 10%, Creatinine is 72 umol/L, and Haemoglobin is 13.2 g/dL.

WHAT I DID NOT OPEN
family-history anamnesis, because the information was not explicitly requested by the moderator and is not critical for the immediate decision based on the opened documents.

WHAT THIS SUPPORTS
Findings that argue FOR sampling this patient now:
PI-RADS 5 finding from the mpMRI report.
Prior positive biopsy history.
PSA velocity of 35.73 ng/mL/yr.

Findings that argue AGAINST sampling this patient now:
Prior positive biopsy status, as per the Expert-Cohort criterion.

WHERE THIS LEANS
The findings strongly support proceeding with further investigation given the high-risk MRI finding and the prior positive biopsy, aligning with the Expert-Cohort's deferral criterion.
LEAN: defer

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (clear). Last value 160.00 ng/mL over 4 points spanning 29 months; velocity +51.87 ng/mL per year; doubling time about 10 months.
PROJECTION at 6 months: 618.3 ng/mL, conformal 95% band 177.4-2155.0.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: NO BIOPSY   p(biopsy) = 0.31
  uncertainty  +/- 0.15 epistemic (95% band 0.01-0.61), of which 0.00 comes from values that had to be imputed
  reliability  MODERATE ('supports' tier) — out-of-fold it was right 71% of the time over the 24 labelled cases in this tier

What moved me most across the labelled series: prior positive biopsy, no prior biopsy, free PSA < 15%, DWI restriction in the report, lesion >= 15 mm in the report, suspicious DRE. Out-of-fold AUC 0.794. I am the only expert that has read the report's wording, and I still cannot see the prior grade or the
surveillance history: those are in the notes, and the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  DEFER, p(biopsy)=0.40  ('discuss' tier)
  EXPERT-FUSION      DEFER, p(biopsy)=0.31  ('supports' tier, fusion_full)
  EXPERT-LIBRARY     DEFER, p(biopsy)=0.00  (identical panel in the series)
  EXPERT-COHORT      DEFER  (rule psa_ge_20)

  documented prior grade in the opened documents: GG 2 ("Gleason 3+4")

RULE THAT FIRED: identical precedent in the labelled series — carried by EXPERT-LIBRARY.
PANEL ANSWER: NO BIOPSY. The labelled series contains this exact panel; the library returns the reading urologist's own decision for it. Out of sample this rung never fires.

Confidence the trace model expects here: clear. Weights it expects: vol=noted, pirads=decisive, age=important, dre=noted, psa=decisive, bx=decisive.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents opened by the registrar appear to have addressed all the moderator's questions. The `previous_notes` provided the Gleason/ISUP grade (Gleason 3+4) and the number of biopsy sessions (one), and confirmed no surveillance protocol. The `radiology_report` provided lesion details, the `psa_trend` provided serial PSA values, and the `laboratory_results` provided free-PSA fraction, renal function, and haemoglobin.

ALIGNMENT WITH THE PANEL
The retrieved evidence, specifically the Gleason 3+4 grade from the notes and the PI-RADS 5 finding from the report, aligns with the PANEL-PROTOCOL's decision of NO BIOPSY, which was driven by the EXPERT-LIBRARY precedent.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade (Gleason or ISUP) of the prior positive biopsy? Answered by the `previous_notes`: Gleason 3+4.
Q2. What is the number and dates of prior biopsy sessions, and is the patient on a surveillance protocol with a confirmatory biopsy due? Answered by the `previous_notes`: One session occurred, and there is no surveillance protocol mentioned.
Q3. Given the PI-RADS 5 and prior positive biopsy, does the patient meet the criteria for immediate treatment as suggested by the closest precedent? This question is addressed by the panel's conclusion, which is based on the precedent.

WHAT CARRIES WEIGHT, AND WHY
The most relevant variables are the PI-RADS 5 finding, which is decisive per the EAU guideline, and the prior positive biopsy status, which triggered the Expert-Cohort deferral criterion. These two factors strongly support the panel's deferral decision.

MY SUGGESTION TO THE CHAIR
I suggest the decision should stand as NO BIOPSY, as the retrieved facts, particularly the prior positive biopsy status and the high-risk MRI finding, align with the panel's conclusion derived from the Expert-Library precedent.

VERDICT: ready | SUGGEST: defer | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: NO BIOPSY   (confidence: clear)

The decision is to defer biopsy because the evidence converged on a negative recommendation, driven primarily by the Expert-Library precedent of an identical panel. This deferral is supported by the Expert-Cohort criterion, which defers based on the prior positive biopsy status, and the retrieved finding that the prior biopsy grade was Gleason 3+4. The rising PSA trajectory is consistent with the known disease, and the high-risk PI-RADS 5 finding aligns with the established management pathway for this clinical scenario.

What carried weight: vol=noted, pirads=decisive, age=important, dre=noted, psa=decisive, bx=decisive
Documents this conference opened: radiology_report, psa_trend, previous_notes, laboratory_results
